Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Funda Meric-Bernstam

Showing results (541-550 of 643) with videos related to

Pageof 65
Sort By:
Molecular Cancer Research : MCR|December 16, 2020
Molecular Profiling of Metastatic Bladder Cancer Early-Phase Clinical Trial Participants Predicts Patient OutcomesOmar Alhalabi, Andrew W Hahn, Pavlos Msaouel, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 20, 2022
Induction chemotherapy with or without erlotinib in patients with head and neck squamous cell carcinoma amenable for surgical resectionXiuning Le, Frederico O Gleber-Netto, M Laura Rubin, et al.
Journal for Immunotherapy of Cancer|June 24, 2026
Artificial intelligence-guided analysis of the tumor microenvironment predicts response to pembrolizumab in rare tumorsMohamed H Derbala, Bettzy Stephen, Woochan Hwang, et al.
NPJ Precision Oncology|July 27, 2025
IL-6 predicts CDK4/6 inhibitor resistance, identifying STAT3 as a target in HR + /HER2-negative metastatic breast cancerNicole M Kettner, Tuyen N Bui, Juliana Navarro-Yepes, et al.
ESMO Open|October 24, 2020
Responsiveness to immune checkpoint inhibitors versus other systemic therapies in RET-aberrant malignanciesAparna Hegde, Alexander Y Andreev-Drakhlin, Jason Roszik, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|October 4, 2020
TRPS1: a highly sensitive and specific marker for breast carcinoma, especially for triple-negative breast cancerDi Ai, Jun Yao, Fei Yang, et al.
Journal of the National Cancer Institute|July 16, 2026
Recurrence Score® gene group components and outcomes in the RxPONDER trial (SWOG S1007)Yara Abdou, Jess Hoag, William E Barlow, et al.
Blood Advances|December 3, 2021
Epstein Barr virus-positive B-cell lymphoma is highly vulnerable to MDM2 inhibitors in vivoXiaoshan Zhang, Ran Zhang, Chenghui Ren, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 22, 2022
Natural History and Characteristics of ERBB2-mutated Hormone Receptor-positive Metastatic Breast Cancer: A Multi-institutional Retrospective Case-control Study from AACR Project GENIEMichele L LeNoue-Newton, Sheau-Chiann Chen, Thomas Stricker, et al.
NPJ Precision Oncology|October 27, 2022
Challenges and opportunities associated with the MD Anderson IMPACT2 randomized study in precision oncologyHenry Hiep Vo, Siqing Fu, David S Hong, et al.
Pageof 65

Showing results (541-550 of 643) with videos related to

Sort By:
Pageof 65
Molecular Cancer Research : MCR|December 16, 2020
Molecular Profiling of Metastatic Bladder Cancer Early-Phase Clinical Trial Participants Predicts Patient OutcomesOmar Alhalabi, Andrew W Hahn, Pavlos Msaouel, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 20, 2022
Induction chemotherapy with or without erlotinib in patients with head and neck squamous cell carcinoma amenable for surgical resectionXiuning Le, Frederico O Gleber-Netto, M Laura Rubin, et al.
Journal for Immunotherapy of Cancer|June 24, 2026
Artificial intelligence-guided analysis of the tumor microenvironment predicts response to pembrolizumab in rare tumorsMohamed H Derbala, Bettzy Stephen, Woochan Hwang, et al.
NPJ Precision Oncology|July 27, 2025
IL-6 predicts CDK4/6 inhibitor resistance, identifying STAT3 as a target in HR + /HER2-negative metastatic breast cancerNicole M Kettner, Tuyen N Bui, Juliana Navarro-Yepes, et al.
ESMO Open|October 24, 2020
Responsiveness to immune checkpoint inhibitors versus other systemic therapies in RET-aberrant malignanciesAparna Hegde, Alexander Y Andreev-Drakhlin, Jason Roszik, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|October 4, 2020
TRPS1: a highly sensitive and specific marker for breast carcinoma, especially for triple-negative breast cancerDi Ai, Jun Yao, Fei Yang, et al.
Journal of the National Cancer Institute|July 16, 2026
Recurrence Score® gene group components and outcomes in the RxPONDER trial (SWOG S1007)Yara Abdou, Jess Hoag, William E Barlow, et al.
Blood Advances|December 3, 2021
Epstein Barr virus-positive B-cell lymphoma is highly vulnerable to MDM2 inhibitors in vivoXiaoshan Zhang, Ran Zhang, Chenghui Ren, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 22, 2022
Natural History and Characteristics of ERBB2-mutated Hormone Receptor-positive Metastatic Breast Cancer: A Multi-institutional Retrospective Case-control Study from AACR Project GENIEMichele L LeNoue-Newton, Sheau-Chiann Chen, Thomas Stricker, et al.
NPJ Precision Oncology|October 27, 2022
Challenges and opportunities associated with the MD Anderson IMPACT2 randomized study in precision oncologyHenry Hiep Vo, Siqing Fu, David S Hong, et al.
Pageof 65